Androgen receptor antagonist

DRUG CLASS:

Androgen receptor antagonist

News alerts, weekly reports and conference planners

Related drugs:

No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	apalutamide Sensitive: A1 - Approval apalutamide Sensitive : A1	apalutamide Sensitive: A1 - Approval apalutamide Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	histrelin acetate + nilutamide Sensitive: A2 - Guideline histrelin acetate + nilutamide Sensitive : A2	histrelin acetate + nilutamide Sensitive: A2 - Guideline histrelin acetate + nilutamide Sensitive : A2
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	goserelin acetate + nilutamide Sensitive: A2 - Guideline goserelin acetate + nilutamide Sensitive : A2	goserelin acetate + nilutamide Sensitive: A2 - Guideline goserelin acetate + nilutamide Sensitive : A2
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	triptorelin + nilutamide Sensitive: A2 - Guideline triptorelin + nilutamide Sensitive : A2	triptorelin + nilutamide Sensitive: A2 - Guideline triptorelin + nilutamide Sensitive : A2
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	leuprolide acetate + nilutamide Sensitive: A2 - Guideline leuprolide acetate + nilutamide Sensitive : A2	leuprolide acetate + nilutamide Sensitive: A2 - Guideline leuprolide acetate + nilutamide Sensitive : A2
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	EPI-7386 Sensitive: B - Late Trials EPI-7386 Sensitive : B	EPI-7386 Sensitive: B - Late Trials EPI-7386 Sensitive : B
AR positive	Breast Cancer	AR positive	Breast Cancer	GT0918 Sensitive: C2 – Inclusion Criteria GT0918 Sensitive : C2	GT0918 Sensitive: C2 – Inclusion Criteria GT0918 Sensitive : C2
AR F877L	Prostate Cancer	AR F877L	Prostate Cancer	apalutamide Resistant: C3 – Early Trials apalutamide Resistant : C3	apalutamide Resistant: C3 – Early Trials apalutamide Resistant : C3
AR overexpression	Triple Negative Breast Cancer	AR overexpression	Triple Negative Breast Cancer	TAK 700 Sensitive: C3 – Early Trials TAK 700 Sensitive : C3	TAK 700 Sensitive: C3 – Early Trials TAK 700 Sensitive : C3
AR T878A	Prostate Cancer	AR T878A	Prostate Cancer	apalutamide Resistant: C3 – Early Trials apalutamide Resistant : C3	apalutamide Resistant: C3 – Early Trials apalutamide Resistant : C3
PTEN expression	Prostate Cancer	PTEN expression	Prostate Cancer	leuprolide acetate + apalutamide Sensitive: C3 – Early Trials leuprolide acetate + apalutamide Sensitive : C3	leuprolide acetate + apalutamide Sensitive: C3 – Early Trials leuprolide acetate + apalutamide Sensitive : C3
PTEN deletion	Prostate Cancer	PTEN deletion	Prostate Cancer	apalutamide Sensitive: C3 – Early Trials apalutamide Sensitive : C3	apalutamide Sensitive: C3 – Early Trials apalutamide Sensitive : C3
SNAI2 deletion	Prostate Cancer	SNAI2 deletion	Prostate Cancer	abiraterone acetate + degarelix + bicalutamide implant Sensitive: C3 – Early Trials abiraterone acetate + degarelix + bicalutamide implant Sensitive : C3	abiraterone acetate + degarelix + bicalutamide implant Sensitive: C3 – Early Trials abiraterone acetate + degarelix + bicalutamide implant Sensitive : C3
SPOP mutation	Prostate Cancer	SPOP mutation	Prostate Cancer	enzalutamide + abiraterone acetate + apalutamide Sensitive: C3 – Early Trials enzalutamide + abiraterone acetate + apalutamide Sensitive : C3	enzalutamide + abiraterone acetate + apalutamide Sensitive: C3 – Early Trials enzalutamide + abiraterone acetate + apalutamide Sensitive : C3
HR positive + AR positive	HER2 Negative Breast Cancer	HR positive + AR positive	HER2 Negative Breast Cancer	fulvestrant + GT0918 Sensitive: C3 – Early Trials fulvestrant + GT0918 Sensitive : C3	fulvestrant + GT0918 Sensitive: C3 – Early Trials fulvestrant + GT0918 Sensitive : C3
BRCA2 A902fs*2	Prostate Cancer	BRCA2 A902fs*2	Prostate Cancer	abiraterone acetate + bicalutamide implant + leuprorelin depot Resistant: C4 – Case Studies abiraterone acetate + bicalutamide implant + leuprorelin depot Resistant : C4	abiraterone acetate + bicalutamide implant + leuprorelin depot Resistant: C4 – Case Studies abiraterone acetate + bicalutamide implant + leuprorelin depot Resistant : C4
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	apalutamide Sensitive: D – Preclinical apalutamide Sensitive : D	apalutamide Sensitive: D – Preclinical apalutamide Sensitive : D
AR splice variant 7 expression	Prostate Cancer	AR splice variant 7 expression	Prostate Cancer	EPI-7386 Sensitive: D – Preclinical EPI-7386 Sensitive : D	EPI-7386 Sensitive: D – Preclinical EPI-7386 Sensitive : D
AR positive	Triple Negative Breast Cancer	AR positive	Triple Negative Breast Cancer	apalutamide Sensitive: D – Preclinical apalutamide Sensitive : D	apalutamide Sensitive: D – Preclinical apalutamide Sensitive : D
AR overexpression	Prostate Cancer	AR overexpression	Prostate Cancer	BMS-641988 Resistant: D – Preclinical BMS-641988 Resistant : D	BMS-641988 Resistant: D – Preclinical BMS-641988 Resistant : D
AR T877A	Prostate Cancer	AR T877A	Prostate Cancer	BMS-641988 Resistant: D – Preclinical BMS-641988 Resistant : D	BMS-641988 Resistant: D – Preclinical BMS-641988 Resistant : D
PTEN deletion	Prostate Cancer	PTEN deletion	Prostate Cancer	apalutamide + AZD4635 Sensitive: D – Preclinical apalutamide + AZD4635 Sensitive : D	apalutamide + AZD4635 Sensitive: D – Preclinical apalutamide + AZD4635 Sensitive : D
AR positive	Prostate Cancer	AR positive	Prostate Cancer	GT0918 Sensitive: D – Preclinical GT0918 Sensitive : D	GT0918 Sensitive: D – Preclinical GT0918 Sensitive : D
AR positive	Triple Negative Breast Cancer	AR positive	Triple Negative Breast Cancer	HC-1119 Sensitive: D – Preclinical HC-1119 Sensitive : D	HC-1119 Sensitive: D – Preclinical HC-1119 Sensitive : D

Androgen receptor antagonist

Androgen receptor antagonist

Associations(24)

Associations
(24)